Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

Photo: Deal to progress Alzheimers vaccine

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

More on the subject:

Related articles

Photo

News • Human cytomegalovirus

How HMCV evades the immune system

Human cytomegalovirus (HCMV) is a major global health burden that causes lifelong infection in humans. Researchers have now shown how the virus escapes immune surveillance.

Photo

Sponsored • Produced in partnership with FUJIFILM Wako

Beta-D-glucan testing: More than a single result

Invasive fungal infections remain among the most challenging diagnoses in clinical microbiology. Beta-D-glucan (BDG) testing has emerged as a valuable non-invasive biomarker – but its true utility…

Photo

Interview • Resilience in healthcare

“We need redundancy at every level”

The threat of hybrid attacks in Germany is increasing. In this exclusive interview with MedLabPortal, DGKL CEO Jan Wolter highlights existing vulnerabilities and calls on policymakers to take action.

Subscribe to Newsletter